 Media reports of dramatic consequences of incorrect gene test interpretation and use combined with allegations of aggressive billing tactics drove the NTRA shares reeling. This negative publicity alienated investors who seem to miscalculate its impact on NTRAs revenue, opening an opportunity for contrarian traders as the company continues executing its growth strategy. 